← Back to Screener
Aardvark Therapeutics, Inc. Common Stock (AARD)
Price$3.68
Momentum ScoreD
Favorite Metrics
Price vs S&P 500 (26W)-70.64%
Price vs S&P 500 (4W)-33.13%
VGM Score20.84
Market Capitalization$80.28M
All Metrics
Book Value / Share (Quarterly)$3.99
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-2.83
Price vs S&P 500 (YTD)-81.00%
EPS (TTM)$-3.21
10-Day Avg Trading Volume0.16M
EPS Excl Extra (TTM)$-3.21
EPS (Annual)$-2.93
ROI (Annual)-54.01%
Cash / Share (Quarterly)$4.18
ROA (Last FY)-49.15%
EBITD / Share (TTM)$-3.43
Cash Flow / Share (Annual)$-2.49
P/B Ratio0.92x
P/B Ratio (Quarterly)0.95x
Net Income / Employee (Annual)$-1,439,800
Net Interest Coverage (TTM)-5.16x
ROA (TTM)-56.29%
EPS Incl Extra (Annual)$-2.93
Current Ratio (Annual)10.61x
Quick Ratio (Quarterly)7.86x
3-Month Avg Trading Volume0.25M
52-Week Price Return-66.32%
Revenue / Employee (TTM)$0
52-Week High$17.94
EPS Excl Extra (Annual)$-2.93
26-Week Price Return-59.26%
Quick Ratio (Annual)10.43x
13-Week Price Return-30.14%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)8.06x
Enterprise Value$17.85M
Revenue / Employee (Annual)$0
Cash / Share (Annual)$5.04
3-Month Return Std Dev109.58%
Net Income / Employee (TTM)$-1,746,700
ROE (Last FY)-54.01%
EPS Basic Excl Extra (Annual)$-2.93
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-3.21
ROI (TTM)-61.71%
Revenue / Share (Annual)$0.00
Price vs S&P 500 (52W)-93.37%
Year-to-Date Return-69.98%
5-Day Price Return-4.14%
EPS Normalized (Annual)$-2.93
Month-to-Date Return-4.14%
EBITD / Share (Annual)$-3.19
EPS Basic Excl Extra (TTM)$-3.21
P/B Ratio (Annual)2.68x
Book Value / Share (Annual)$4.89
Price vs S&P 500 (13W)-40.64%
Beta4.36x
Revenue / Share (TTM)$0.00
ROE (TTM)-61.71%
52-Week Low$3.35
mGradeD
vgmGradeD
Show chart for
Earnings Surprise History
Q1 26-0.99est. -0.89
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
4.39
4.39
4.11
4.11
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
AARDAardvark Therapeutics, Inc. Common Stock | — | — | D | $3.68 |
| LLYEli Lilly & Co. | D | B | B | $1131.42 |
| JNJJohnson & Johnson | D | C | B | $232.77 |
| ABBVABBVIE INC. | D | C | C | $227.23 |
| MRKMerck & Co., Inc. | C | C | B | $120.79 |
| NVSNovartis AG | C | C | C | $149.16 |
| AZNAstraZeneca PLC | D | B | C | $185.95 |
| NVONovo-Nordisk A/S | B | B | B | $42.96 |
| ABTAbbott Laboratories | C | C | D | $91.07 |
| PFEPfizer Inc. | B | C | C | $26.04 |
| BMYBristol-Myers Squibb Co. | B | C | B | $57.27 |
About
Aardvark Therapeutics is a clinical-stage biopharmaceutical company developing small-molecule therapeutics that target Bitter Taste Receptors (TAS2Rs) to treat metabolic and hunger-associated conditions. The company's lead candidate, ARD-101, is an oral gut-restricted TAS2R agonist currently in Phase 3 clinical trials for hyperphagia associated with Prader-Willi Syndrome.